is an important cause of bleeding in patients with cirrhosis associated with portal hypertension. Histologically, the condition is characterized by dilation of the mucosal and submucosal vessels ...

Butt, who wasn’t involved with this study, presented separate research (abstract 4152) on statins in MASH patients with ...

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...

Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive ...

Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising ...

Causes of portal hypertension can be prehepatic (such as portal vein thrombosis), hepatic (commonly liver cirrhosis and hepatic fibrosis) or posthepatic (such as hepatic vein obstruction).